Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
443.51
-3.32 (-0.74%)
Jun 8, 2026, 1:31 PM EDT - Market open
Vertex Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 4,338 | 3,953 | -535.6 | 3,620 | 3,322 | 2,342 |
Depreciation & Amortization | 217.3 | 209.8 | 207.2 | 181.3 | 148.3 | 125.6 |
Stock-Based Compensation | 686.2 | 685.9 | 698.5 | 581.2 | 491.3 | 441.4 |
Other Adjustments | -292.9 | -18.4 | -347.9 | -579.1 | -172.5 | -160.4 |
Change in Receivables | -137.9 | -347.3 | -99.3 | -84.1 | -358.6 | -274.7 |
Changes in Inventories | -454.8 | -524.2 | -517.3 | -322.9 | -136.4 | -92.8 |
Changes in Accounts Payable | 46.2 | 36.8 | 49.5 | 48.7 | 120.8 | 31.9 |
Changes in Accrued Expenses | -94.5 | -116.9 | 212.9 | 429.4 | 542.5 | 305.4 |
Changes in Other Operating Activities | -44.9 | -247.5 | -160.6 | -336.8 | 172.5 | -75 |
Operating Cash Flow | 4,241 | 3,631 | -492.6 | 3,537 | 4,130 | 2,644 |
Operating Cash Flow Growth | - | - | - | -14.35% | 56.23% | -18.75% |
Capital Expenditures | -530.3 | -437.6 | -297.7 | -200.4 | -204.7 | -235 |
Purchases of Intangible Assets | - | - | -187.7 | -58 | - | - |
Purchases of Investments | -7,257 | -6,397 | -7,696 | -3,787 | -988.6 | -605.2 |
Proceeds from Sale of Investments | 6,469 | 5,897 | 4,482 | 934.2 | 920 | 499.3 |
Payments for Business Acquisitions | - | - | - | - | -47.8 | - |
Other Investing Activities | -19.4 | -24.7 | -54 | -31 | - | - |
Investing Cash Flow | -1,322 | -945.4 | -3,770 | -3,142 | -321.1 | -340.9 |
Long-Term Debt Issued | - | - | - | - | - | 28.3 |
Long-Term Debt Repaid | -4.1 | -5.4 | -33.6 | -44.9 | -85.5 | -47 |
Net Long-Term Debt Issued (Repaid) | -4.1 | -5.4 | -33.6 | -44.9 | -85.5 | -18.7 |
Issuance of Common Stock | 138 | 127.7 | 114.6 | 134.6 | 186.3 | 102 |
Repurchase of Common Stock | -2,256 | -2,387 | -1,582 | -653.7 | -172 | -1,561 |
Net Common Stock Issued (Repurchased) | -2,118 | -2,260 | -1,468 | -519.1 | 14.3 | -1,459 |
Other Financing Activities | 2.5 | 3.7 | 6.2 | 1.8 | 3.5 | - |
Financing Cash Flow | -2,120 | -2,261 | -1,495 | -562.2 | -67.7 | -1,478 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 20.1 | 90.9 | -42.6 | 26.9 | -29.2 | -13.4 |
Net Cash Flow | 819.5 | 515.6 | -5,800 | -139.7 | 3,712 | 811.2 |
Free Cash Flow | 3,710 | 3,194 | -790.3 | 3,337 | 3,925 | 2,409 |
Free Cash Flow Growth | 16.17% | - | - | -14.99% | 62.97% | -19.55% |
FCF Margin | 30.37% | 26.61% | -7.17% | 33.81% | 43.95% | 31.80% |
Free Cash Flow Per Share | 14.42 | 12.38 | -3.06 | 12.81 | 15.15 | 9.27 |
Levered Free Cash Flow | 2,440 | 2,868 | -1,075 | 3,374 | 3,880 | 2,384 |
Unlevered Free Cash Flow | 3,070 | 2,474 | -4.02 | 2,966 | 4,024 | 2,447 |